Abstract #422362: First-in-human (FIH) phase I dose escalation study (Part A) of the first oral allosteric modulator of phosphoinositide 3kinase inhibitor delta (PI3Kδ) roginolisib in patients with advanced cancer and dose confirmation in Uveal Melanoma (Part B)

AM Di Giacomo¹, F Santangelo¹, G Amato¹, Elena Simonetti¹, J Graham², M Lahn³, G Di Conza³, T Hammett³, R Zorrilla³, M Durini⁴, T Zivang⁵, L Tadepallv⁵, P Brodin⁵, M Occhipinti⁶, M Simonelli⁷, C Carlo-Stella⁷, A Santoro⁷, P Spiliopoulou⁸, A Abdul-Ahad⁹, R Sniider⁹ TRJ Evans^{10*}, M Maio^{1*}

¹University of Siena and Center for Immuno-Oncology, Department of Oncology, University Hospital, Siena, Italy, ³Medical Oncology Dept BWSCC-Beatson West of Scotland Cancer Centre, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom, ³R&D Department, iOnctura SA, Geneva, Switzerland, ⁴Labcorp Clinical Development Ltd, Via Raimondo Montecuccoli 20/1, Milano, Italy, ⁹Women's and Clyde, Glasgow, United Kingdom, ³R&D Department, iOnctura SA, Geneva, Switzerland, ⁴Labcorp Clinical Development Ltd, Via Raimondo Montecuccoli 20/1, Milano, Italy, ⁹Women's and Clyde, Glasgow, United Kingdom, ³R&D Department, iOnctura SA, Geneva, Switzerland, ⁴Labcorp Clinical Development Ltd, Via Raimondo Montecuccoli 20/1, Milano, Italy, ⁹Women's and Clyde, Glasgow, United Kingdom, ³R&D Department, iOnctura SA, Geneva, Switzerland, ⁴Labcorp Clinical Development Ltd, Via Raimondo Montecuccoli 20/1, Milano, Italy, ⁹Women's and Clyde, Glasgow, United Kingdom, ³R&D Department, iOnctura SA, Geneva, Switzerland, ⁴Labcorp Clinical Development Ltd, Via Raimondo Montecuccoli 20/1, Milano, Italy, ⁹Women's and Clyde, Glasgow, United Kingdom, ³R&D Department, iOnctura SA, Geneva, Switzerland, ⁴Labcorp Clinical Development Ltd, Via Reisondo Montecuccoli 20/1, Milano, Italy, ⁹Drug Development Program, Phase I Unit, Princess Margaret Hospital, University Avenue, Toronto (ON), Canada, ⁹BOTh Analytics GbmH Muchen, Germany, ¹⁰Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom. *Asterisk indicated both are senior authors

BACKGROUND

•PIK3CD expression is correlated with immune suppressive immune cells, such as Trag cells •Highly selective PI3Kd inhibition results in blocking tumour-cell intrinsic and extrinsic pathways

•Roginolisib (formerly IOA-244) has a unique mechanism of action as an allosteric modulator and a highly selective PI3Kd inhibitor

OBJECTIVES

Primary:

Safety and tolerability of escalating doses of IOA-244 to the predicted biological effective dose (BED)

Secondary:

To assess the pharmacokinetic (PK) profile

Characterize pharmacodynamic (PD) effect as determined by inhibition of CD63 expression on basophils in response to IOA-244

To document antitumor activity, including overall response rate (ORR), duration of response (DoR), progression free survival (PFS) and overall survival (OS)

Exploratory:

Changes in immune cell numbers within pre- and post-treatment biopsies and in the circulating blood (multiplex IHC and Cytometry by Time of Flight, CyTOF)

METHODS

Design: 3+3 cohort dose escalation

Patients Eligibility

≥18 years of age with the following:

A performance status of ≤2 on the ECOG scale

•Histological or cytological evidence of a diagnosis of cancer that is advanced and/or metastatic disease for mesothelioma, cutaneous, and uveal melanoma or non-Hodgkin lymphoma follicular lymphoma (NHL-FL) Adequate organ functioning

Assessments:

•Toxicities graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Standard laboratory hematology and chemistry

• RECIST 1.1. based evaluation (ORR) - exploratory studies with radiomics were conducted, including assessing changes in spleen volume


Benefit/Risk for Recommended Phase 2 Dose (RP2D)

BOTh - Burden of Therapy (Toxicity)

BOTh [™] is a highly sensitive, novel methodology that utilises patient-level data to derive a quantitative estimate for the "Burden of Therapy/Toxicity" (BOTh) that pts experience on each day of a clinical study . Reference for BOTh: Abdul-ahad et al. Contemporary Clinical Trials Communications 4 (2016) 186e191

RESULTS

Table 1. Demography and Baseline Characteristics



Grade 3 Grade 3 Grade 3 Grade 4 Grade 5

Table 2: Safety (All Cause and Drug-related)

ST: solid tumour, NHL: non-Hodgkin lymphoma, UM: uveal melanoma *The CTCAE Grade 5 toxicities observed were associated with tumour progression and **NOT** considered related to

treatment "The Grade 3 related TEAEs resolved whilst continuing on treatment. (20 mg – Platelet Count decrease, 80 mg

Figure 1: Burden of Therapy/Toxicity (BOTh) for all cause TEAEs




Figure 1: Long-term treatment with roginolisib shown for Grade 1 (grey), Grade 2 (orange), Grade 3 (blue) all-cause toxicity for patients receiving 80 mg (n= 28) vs all other dose levels (n=16). Panel A: all patients. Panel B: one patient with uveal melanoma had an initial increase and reduction in ALT coinciding with viral infection Excluding this patient identifies this patient as the main driver for Grade 3 toxicity evaluation in uveal melanoma.

Anti-tumour activity

Figure 2: Spider plots for uveal melanoma patients





Figure 2: Spider plot of % change in target lesions for all UM patients with measurable disease as per RECIST 1.1 by dose level

beyond 6 months 10 mg 20 mg 40 mg 80 mg

Figure 3: Time on roginolisib for UM patients - ≈50% treated

Figure 3: Bar chart for patients with uveal melanoma (n=29) (11/29 pts (45%) continue on roginolisil

Figure 4: Proteomic analysis of plasma cytokine/chemokine



days for all patients with uveal melanoma (blue line=median). Panel A: IL15 level remain stable over the treatment period: Papel B and C: JENV, CXCI 10 appear to be stable or slightly reduced over the treatment period. The Treg inducing chemokine CCL22 is reduced and continues a trend of reduction over time

Figure 5: Changes in spleen volume using Radiomics assessment in UM natiente





Figure 5: A treatment-related reduction of spleen volume is observed in all 4 patients analysed

Figure 6: Survival Rate (%) of UM patients at landmark time points (6, 9 and 12 months)

% Survival (95% Cl)	Roginolisib (ongoing)				
	Part A (n=9)	Part 8.1 (n=7)	Part B.2 (n=13)	Overall (n=29)	After CPI (n=318)
6 months	88.9% (43.3%, 98.4%)	100% (-)	75.0% (29.8%, 93.4%)	87.4% (65.8%, 95.8%)	58.1% (32.3%, 63.5%)
9 months	88.9% (43.3%, 98.4%)	71.4% (25.8%, 92.0%)	75.0% (29.8%, 93.4%)	78.7% (56.0%, 90.5%)	42.4% (36.6%, 48.1%
12 months	66.7% (28.2%, 87.8%)	71.4% (25.8%, 92.0%)	8	67.3% (42.7%, 83.2%)	34.2% (28.6, 39.9%)

Figure 6: UM patients treated with roginolisib (n=29) compared to patients treated with different drugs after progression on prior checkpoint inhibitor (CPI) (n=318) (Historic external control Rantala et al 2019) Ref: Rantala et al Melanoma Research 2019, 29:561-568

Figure 7: Kaplan-Meier (KM) Plots for uveal melanoma patients (OS data still evolving)




This translates to long OS for patients treated in the dose escalation part (Part A), initial expansion cohort (part B.1) and final expansion cohort (Part B.2). The median OS is only available for Part A (20.8 mo)


Figure 7: Patients treated with roginolisib have extended time on treatment (ToTx), beyond

progression, due to the favourable toxicity profile

The median has not been reached for Parts B.1 and B 2

Figure 8: KM Plots for uveal melanoma patients by number of prior lines of treatment (Tx) (OS data still evolving)





CONCLUSIONS

•Roginolisib, given as an oral monotherapy, has a favourable toxicity profile compared to 1st generation PI3K₀ Inhibitors (especially in patients treated >6 months)

 Roginolisib increases plasma IL-15, IFNy while reducing CCL22 levels

•Correlation studies with mass cytometry (Treg, CD8 and NK cell population) are ongoing

•Long term administration of roginolosib (>6 months) translates to encouraging Overall Survival (>20 months)